JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model

Blood

Volumn 124, Issue 20, 2014, Pages 3092-3100

  Degryse, Sandrine ^a,b   De Bock, Charles E ^a,b   Cox, Luk ^a,b   Demeyer, Sofie ^a,b   Gielen, Olga ^a,b   Mentens, Nicole ^a,b   Jacobs, Kris ^a,b   Geerdens, Ellen ^a,b   Gianfelici, Valentina ^c   Hulselmans, Gert ^b   Fiers, Mark ^a,b   Aerts, Stein ^b   Meijerink, Jules P ^d   Tousseyn, Thomas ^e   Cools, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; JANUS KINASE 1; JANUS KINASE 3; RETROVIRUS VECTOR; RUXOLITINIB; STAT5 PROTEIN; TOFACITINIB; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW PROGENITOR CELL; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL MUTANT; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HEMATOPOIETIC CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKOCYTE COUNT; MACROPHAGE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; T CELL LEUKEMIA; TISSUE SECTION; WESTERN BLOTTING; ACUTE DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; LEUKEMIA, T-CELL; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ACUTE DISEASE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; JANUS KINASE 1; JANUS KINASE 3; LEUKEMIA, T-CELL; MALE; MICE; MICE, INBRED BALB C; MUTATION; PIPERIDINES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84911909502     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-566687     Document Type: Article

References (29)

1. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601-2613.
2. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol. 2004;41(6-7): 727-737.
3. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet. 2011; 43(10):932-939.
4. De Keersmaecker K, Atak ZK, Li N, et al. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet. 2013;45(2): 186-190.
5. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
6. Flex E, Petrangeli V, Stella L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205(4):751-758.
7. Asnafi V, Le Noir S, Lhermitte L, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol. 2010;148(1): 178-179.
8. Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53(4):309-316.
9. Walters DK, Mercher T, Gu T-L, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
10. Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasaltype natural killer cell lymphoma. Leukemia. 2014;28(2):338-348.
11. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013; 45(8):937-941.
12. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Davé UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood. 2011;118(14): 3911-3921.
13. Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov. 2012;2(7):591-597.
14. Cornejo MG, Kharas MG, Werneck MB, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood. 2009; 113(12):2746-2754.
15. Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through gc-containing cytokine receptors. Chem Biol. 2011;18(3):314-323.
16. Porcu M, Kleppe M, Gianfelici V, et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood. 2012;119(19):4476-4479.
17. Kleppe M, Soulier J, Asnafi V, et al. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. Blood. 2011; 117(26):7090-7098.
18. Kleppe M, Mentens N, Tousseyn T, Wlodarska I, Cools J. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context. Haematologica. 2011;96(5):779-783.
19. Armstrong F, Brunet de la Grange P, Gerby B, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood. 2009; 113(8):1730-1740.
20. Kalender Atak Z, De Keersmaecker K, Gianfelici V, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes. PLoS ONE. 2012;7(6):e38463.
21. Atak ZK, Gianfelici V, Hulselmans G, et al. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013;9(12):e1003997.
22. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE. 2012;7(10): e46688.
23. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690, 550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24): 8468-8484.
24. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
25. Andraos R, Qian Z, Bonenfant D, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012;2(6):512-523.
26. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353(2):172-187.
27. LaFave LM, Levine RL. JAK2 the future: therapeutic strategies for JAK-dependent malignancies. Trends Pharmacol Sci. 2012; 33(11):574-582.
28. Hanna DM, Fellowes A, Vedururu R, Mechinaud F, Hansford JR. A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy. Haematologica. 2014;99(9):e156-e158.
29. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica. 2013;98(12):1872-1876.